RE: Brilliant End of Year report !!! GO HEMO GO30 Apr 2026 17:59
I love it β€οΈ I love it β€οΈ
Love this bit without changing a single word
Clinical progress: from first-in-human to dose escalation
The defining event of the year was the first-in-human administration of HG-CT-1, our proprietary chimeric antigen receptor T cell ("CAR-T") therapy for adult patients with relapsed or refractory acute myeloid leukaemia ("R/R AML"), on 24 February 2025. This was followed within weeks by confirmation that the first patient had tolerated the treatment well, with no dose-limiting toxicities observed and encouraging early indications of biological activity. A second patient was recruited in March, and a third patient was treated in August, completing the initial dose cohort.
In October 2025, the independent Data Safety Monitoring Board ("DSMB") overseeing the trial reviewed the safety data from all three patients treated at the lowest dose level and recommended that the study proceed with escalation to the second dose level. This is a significant inflection point: it is an external, independent endorsement that HG-CT-1 has an acceptable safety profile at the starting dose, and it opens the path to the dose levels at which meaningful efficacy is most likely to emerge. The DSMB simultaneously authorised the initiation of paediatric enrolment at the same starting dose used in adults.